Fast science—with all its warts—is making unprecedented progress in the fight against COVID-19.

The company behind a now-discredited study on hydroxychloroquine also posted a report that has been cited by Latin American governments recommending ivermectin as a possible coronavirus treatment. Clinicians there say the effects have been extremely damaging.

Our handbook on best practices for quality assurance in biomedicine can help funding agencies shore up research integrity—which is especially needed at a time when mistakes can have outsize effects.

The company had helped develop a tool to aid decision-making in distributing limited medical equipment among coronavirus patients, but two high-profile retractions call into question the validity of Surgisphere’s work in toto.

All authors other than company founder and CEO Sapan Desai were “unable to complete an independent audit of the data,” The Lancet states.

NEJM and The Lancet issue expressions of concern as researchers question where the company got its data on thousands of coronavirus patients.

Early career researchers face unique challenges when a senior collaborator becomes embroiled in allegations of scientific malpractice.

Scientists have raised questions about the dataset published in The Lancet last week that triggered the suspension of clinical trials around the world—and about Surgisphere Corporation, the company behind the study.

Administration officials and lawmakers say the move is to shore up national security threats, but university professors argue such cancellations represent targeted discrimination.